Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT04147949Phase 2Unknown
- Sponsor
- Vistagen Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing AV-101 with Placebo (2 arms). Primary endpoint: Unified Dyskinesia Rating Scale at 14 days. Status: unknown.
02
Drugs
4-chlorokynurenine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT04147949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147949.